Investing News NetworkYour trusted source for investing success

Videos
Companies
Press Releases
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Private Placements
Trending
Trending Articles

7 Biggest Lithium-mining Companies in 2024

Could the Silver Price Really Hit $100 per Ounce? (Updated 2024)

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

Top 10 Oil-producing Countries (Updated 2024)

Where Does Tesla Get its Lithium? (Updated 2024)

Uranium Stocks: 5 Biggest Companies in 2024

How to Invest in OpenAI's ChatGPT (Updated 2024)

Top 4 Largest Lithium Reserves by Country (Updated 2024)

Hydrogen Stocks: 9 Biggest Companies in 2024

Trending Press Releases

SIRONA BIOCHEM Poised for Profitability in 2025 with Anti-Aging Product Rollout

Altech – CERENERGY® First 60 KWh Prototype Online and Achieving Great Results

In Search of Alternative Financing for Critical Minerals Projects

Glencore Loan Facility Closed, Offtakes Executed

Black Mountain: Strategy & Drilling Plans

More Press Releases
Trending Companies

Saga Metals

SAGA:CA

Albemarle Corporation

ALB

Sociedad Quimica y Minera S.A. (SQM)

SQM:NYE

Altech Batteries

ATC:AU
More Companies
Trending Reports

2024 Lithium Market Outlook

Nickel Investor Report

Silver Price Forecast - What Happened And Where Do We Go From Here?

2024 Gold Outlook Report

More Outlook Reports
Resource
Resource
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Tech
Tech
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Life Science
Life Science
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Gold Price
Silver Price
Copper Price
Oil Price
Uranium
Artificial Intelligence
loader

Pardes Biosciences Inc.

NASDAQ:PRDS
Press Releases

Pardes Biosciences Inc is a clinical-stage biopharmaceutical company created for solving pandemic-sized problems, starting with COVID-19. It applies reversible-covalent chemistry to discover and develop novel oral drug candidates. The company's lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19.

Interactive Chart

×